Methicillin-resistant staphylococcus aureus (MRSA) is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin. Some of the most commonly used antibiotics use for the treatment of MRSA include glycopeptides and lipoglycopeptides, oxazolidinones, lipopeptides, cephalosporin, and others. These drugs are used to kill or restrain Methicillin-resistant staphylococcus aureus infection.
Market Dynamics
Rising number of pipeline products, and increasing product launches & approval for the treatment of MRSA infection are some of the major factors responsible for the growth of global Methicillin-resistant staphylococcus aureus (MRSA) market. For instance, For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat post-surgical infections of Methicillin-resistant Staphylococcus aureus (MRSA).
Key features of the study:
- This report provides in-depth analysis of the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Methicillin-resistant staphylococcus aureus (MRSA) drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market
Detailed Segmentation:
- Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market, By Drug Class:
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Lipopeptides
- Cephalosporin
- Tetracycline
- Others
- Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market, By Region:
- North America
- By Drug Class:
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Lipopeptides
- Cephalosporin
- Tetracycline
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Class:
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Lipopeptides
- Cephalosporin
- Tetracycline
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class:
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Lipopeptides
- Cephalosporin
- Tetracycline
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class:
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Lipopeptides
- Cephalosporin
- Tetracycline
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class:
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Lipopeptides
- Cephalosporin
- Tetracycline
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class:
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Lipopeptides
- Cephalosporin
- Tetracycline
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Merck & Co., Inc. *
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Pfizer Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Melinta Therapeutics, Inc.
- Cumberland Pharmaceuticals Inc.
- Nabriva Therapeutics Plc.
- Paratek Pharmaceuticals, Inc.
- Debiopharm International SA.
- Innovation Pharmaceuticals Inc.
- Basilea Pharmaceutica Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
